Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103 in HER2-Positive Breast Cancer with Brain Metastases
Go back to Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103 in HER2-Positive Breast Cancer with Brain Metastases| Fabien Corp (NASDAQ: FBIO) | Delayed: 3.08 +0.09 (3.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.99 | 52 Week High | $4.66 | |||
| Open | $2.99 | 52 Week Low | $2.01 | |||
| Day High | $3.12 | P/E | N/A | |||
| Day Low | $2.96 | EPS | $0.00 | |||
| Volume | 443,346 | |||||
| (NASDAQ: MBIO) | Delayed: 0.66 +0.01 (1.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.65 | 52 Week High | $ | |||
| Open | $0.67 | 52 Week Low | $ | |||
| Day High | $0.67 | P/E | N/A | |||
| Day Low | $0.64 | EPS | $ | |||
| Volume | 15,471 | |||||
